PT  - JOURNAL ARTICLE
AU  - Fritz Sörgel
AU  - Jakob J. Malin
AU  - Henning Hagmann
AU  - Martina Kinzig
AU  - Muhammad Bilal
AU  - Dennis A. Eichenauer
AU  - Oliver Scherf-Clavel
AU  - Alexander Simonis
AU  - Lobna El Tabei
AU  - Uwe Fuhr
AU  - Jan Rybniker
TI  - Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis
AID  - 10.1101/2020.10.28.20216887
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.28.20216887
4099  - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20216887.short
4100  - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20216887.full
AB  - Remdesivir, a drug with provisional approval for the treatment of COVID-19, is not recommended in patients with an estimated glomerular filtration rate ≤ 30 mL/min. Here we provide a first detailed pharmacokinetic assessment of remdesivir and its major metabolites in a patient with end stage renal disease on hemodialysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work did not receive any specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethics committee at the university hospital of cologne (Reference: 20-1295)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request